Government
Concerns regarding favoritism to a former commissioner have forced the U.S. Food and Drug Administration to reverse course over a $4.2 million grant to Duke University.
Basel, Switzerland-based Novartis announced that between the ASCO meeting and the 23rd Annual Congress of the European Hematology Association (EHA) meeting being held June 14 to 17 in Stockholm, Sweden, it will be presenting 84 abstracts.
Members of the U.S. Senate are not done with Novartis regarding payment to Trump attorney.
Today the president is expected to propose what could be sweeping reforms to help lower the cost of those medications for consumers.
Barring yet another headline-leading scandal, confrontational tweet or TV talk-show rant, Trump is expected to offer a speech on his administration’s policies toward drug pricing this week.
The Information Technology & Innovation Foundation recently published a report diving into the U.S.’s trade deficits in the life sciences industry worldwide and steps that can be made to keep the biopharma and medical device industries competitive globally.
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
During the 2016 U.S. presidential election, the push for lower drug prices became one of the hot-button topics. Now there appears to be some efforts by advocacy groups and government entities to tackle the subject in several different ways.
The U.S. Supreme Court delivered a blow to the nation’s pharmaceutical industry when it upheld the constitutionality of Inter Partes Review (IPR).
A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.
PRESS RELEASES